https://www.otcmarkets.com/filing/conv_pdf?id=7866
Post# of 8551
(Total Views: 897)
Posted On: 04/11/2020 8:05:28 PM
https://www.otcmarkets.com/filing/conv_pdf?id...W1ZyV1Q83h
P
FORM 15-12G
(Termination of Registration of a Class of Security under Section 12(g))
Filed 04/18/11
Address 4539 METROPOLITAN COURT
FREDERICK, MD, 21704
Telephone 301-874-4890
CIK 0001320869
Symbol BIEL
SIC Code 3845 - Electromedical and Electrotherapeutic Apparatus
Industry Pharmaceuticals
Sector Healthcare
Fiscal Year 12/31
http://www.edgar-online.com
© Copyright 2020, EDGAR Online, a division of Donnelley Financial Solutions. All Rights Reserved.
Distribution and use of this document restricted under EDGAR Online, a division of Donnelley Financial Solutions, Terms of Use.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES
EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934.
Commission File Number 000-51809
Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
Approximate number of holders of record as of the certification or notice date: 171
Pursuant to the requirements of the Securities Exchange Act of 1934 BioElectronics Corporation has caused this certification/notice to be
signed on its behalf by the undersigned duly authorized person.
BioElectronics Corporation
(Exact name of registrant as specified in its charter)
4539 Metropolitan Court, Frederick, Maryland, 21704 (301) 874-4890
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Common Stock, $001 par value
(Title of each class of securities covered by this Form)
None
(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)
Rule 12g-4(a)(1)
Rule 12g-4(a)(2)
Rule 12h-3(b)(1)(i)
Rule 12h-3(b)(1)(ii)
Rule 15d-6
Date: April 18, 2011 By: /s/ Andrew Whelan
Andrew Whelan , President and Chief Financial Offic
P
FORM 15-12G
(Termination of Registration of a Class of Security under Section 12(g))
Filed 04/18/11
Address 4539 METROPOLITAN COURT
FREDERICK, MD, 21704
Telephone 301-874-4890
CIK 0001320869
Symbol BIEL
SIC Code 3845 - Electromedical and Electrotherapeutic Apparatus
Industry Pharmaceuticals
Sector Healthcare
Fiscal Year 12/31
http://www.edgar-online.com
© Copyright 2020, EDGAR Online, a division of Donnelley Financial Solutions. All Rights Reserved.
Distribution and use of this document restricted under EDGAR Online, a division of Donnelley Financial Solutions, Terms of Use.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES
EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934.
Commission File Number 000-51809
Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
Approximate number of holders of record as of the certification or notice date: 171
Pursuant to the requirements of the Securities Exchange Act of 1934 BioElectronics Corporation has caused this certification/notice to be
signed on its behalf by the undersigned duly authorized person.
BioElectronics Corporation
(Exact name of registrant as specified in its charter)
4539 Metropolitan Court, Frederick, Maryland, 21704 (301) 874-4890
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Common Stock, $001 par value
(Title of each class of securities covered by this Form)
None
(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)
Rule 12g-4(a)(1)
Rule 12g-4(a)(2)
Rule 12h-3(b)(1)(i)
Rule 12h-3(b)(1)(ii)
Rule 15d-6
Date: April 18, 2011 By: /s/ Andrew Whelan
Andrew Whelan , President and Chief Financial Offic
(0)
(0)